Across TCGA pan-cancer cohorts, RPL21P109 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RPL21P109’s most consistent transcriptional readouts.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RPL21P109 RNA is repressed in tumor relative to normal tissue. In most cancer types RPL21P109 is over-expressed in tumor, although a few such as KIRC show the opposite, repressed pattern.
KIRC and BRCA are the cancer types where RPL21P109 tumor–normal differential expression is most reproducible.